take a look at NPSP - went down 20% on a AF tweet last week, this morning Adcom notes have been released the stock is back to previous levels. That AF tweet was abosoluty reckless. Unfortunately many investors have been burned and lost big.
I like it too. Bought some shares at 1.54.
Thanks for your input and the highlights on the three programs. Which do you think is the one most likely to drive value and be on interest to partners? Value is very low, but commercialization is also very far, so a partnership deal would help.
What do you make of the management team?
Hey, in case anybody has missed it, Natpara (Natural Paratyroyde Hormone 1-84 is already apporved as Preotact in Europe, since 2006 I believe. Thus Nader, in the last ernings call referred to an extensive database of safety data.
However, it is likely that the AdCom notes and panel will ask questions about Natpara's safety (I suspect cariogenicity --I think Natpara will be administred at 50 micrograms once daily, which is below Preotact 100 micrograms. So the lower dose implies better safety) and if these safety/risks are worth the boost in the patients' quality of life.
Likely, the Adcom's notes tone and content might provoke some fear but at the end of the voting on Sept 12, I believe the outcome should be positive.
Any other thoughts here?
thanks for that reply.... what do you think will happen at adcome? straight approval, or might be black box warnings and things like that? considering Forteo...?
This has been a frustrating stock. No interest what so ever in it. It has falen form a high of almost $50 to 10.... any guesses as what news and when might draw investor interest back into this stock?
does anybody here have an idea about the expected wordlwide sales for Natpara are? will it become a bluckbuster drug, as sensipar? or does it have a smaller market potential? I remember reading $500M.